Meeting
2019 ASCO Annual Meeting
BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): Results from phase III TRIBE and FIRE-3 trials.
Authors
Madiha Naseem
Division of Medical Oncology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA
Madiha Naseem , Shu Cao , Sebastian Stintzing , Fotios Loupakis , Martin D. Berger , Alberto Puccini , Ryuma Tokunaga , Francesca Battaglin , Afsaneh Barzi , Shivani Soni , Joshua Millstein , Mohamed E. Salem , Chiara Cremolini , Wu Zhang , Volker Heinemann , Alfredo Falcone , Heinz-Josef Lenz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3145)
DOI
10.1200/JCO.2019.37.15_suppl.3145
Abstract #
3145
Poster Bd #
137
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405.
First Author: Federico Innocenti
Poster
2011 ASCO Annual Meeting
The predictive value of single nucleotide polymorphisms in the vascular endothelial growth factor system in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy as first-line treatment: Results of the phase III ACT trial NCT00598156 translational study.
First Author: T. Hansen
Poster
2017 Gastrointestinal Cancers Symposium
A multinational, randomized, phase III trial of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab as second-line therapy for metastatic colorectal cancer: Safety analysis of Asian XELIRI project (AXEPT).
First Author: Masato Nakamura
Poster
2014 ASCO Annual Meeting
STEAM: A randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).
First Author: Johanna C. Bendell